TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Short Interest Down 89.3% in August

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) was the target of a large decrease in short interest during the month of August. As of August 15th, there was short interest totalling 175,800 shares, a decrease of 89.3% from the July 31st total of 1,640,000 shares. Currently, 1.0% of the company’s stock are short sold. Based on an average trading volume of 1,020,000 shares, the short-interest ratio is currently 0.2 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $3.00 price objective on shares of TransCode Therapeutics in a research report on Thursday, August 15th.

TransCode Therapeutics Trading Down 2.2 %

TransCode Therapeutics stock traded down $0.01 on Tuesday, hitting $0.27. The company’s stock had a trading volume of 210,768 shares, compared to its average volume of 1,046,823. TransCode Therapeutics has a one year low of $0.22 and a one year high of $128.00. The company has a fifty day moving average price of $0.60 and a 200-day moving average price of $0.77.

Institutional Investors Weigh In On TransCode Therapeutics

A hedge fund recently bought a new stake in TransCode Therapeutics stock. Virtu Financial LLC acquired a new position in shares of TransCode Therapeutics, Inc. (NASDAQ:RNAZ) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 55,329 shares of the company’s stock, valued at approximately $37,000. Virtu Financial LLC owned 0.84% of TransCode Therapeutics as of its most recent SEC filing.

About TransCode Therapeutics

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.